Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

医学 无容量 头颈部 肿瘤科 基底细胞 化疗 头颈部鳞状细胞癌 单克隆抗体 头颈部癌 内科学 癌 单克隆 抗体 免疫疗法 放射治疗 外科 癌症 免疫学
作者
Robert Louis Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,Alexander Dimitrios Colevas,Lisa Francesca Licitra,Kevin Joseph Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis Paul Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark John Lynch,William J. Geese
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:375 (19): 1856-1867 被引量:5083
标识
DOI:10.1056/nejmoa1602252
摘要

BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
billc73完成签到,获得积分20
刚刚
刚刚
1秒前
2秒前
内向的夏寒完成签到,获得积分10
2秒前
慕青的应助被菜鸟学习采纳,获得10
2秒前
2秒前
2秒前
fcc完成签到 ,获得积分10
3秒前
3秒前
3秒前
4秒前
4秒前
小马甲的应助被小生不才采纳,获得10
4秒前
喵不吃鱼完成签到,获得积分10
4秒前
无奈芫完成签到,获得积分20
5秒前
5秒前
yang发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
5秒前
可妍昇发布了新的文献求助10
6秒前
可妍昇发布了新的文献求助10
6秒前
6秒前
6秒前
pjlmky完成签到,获得积分20
6秒前
Shueason完成签到 ,获得积分10
6秒前
6秒前
隐形曼青的应助被眼睛大乐巧采纳,获得10
6秒前
可妍昇发布了新的文献求助10
6秒前
6秒前
发SCI超人发布了新的文献求助10
7秒前
上官若男的应助被林鑫采纳,获得10
7秒前
可妍昇发布了新的文献求助10
7秒前
NexusExplorer的应助被欧耶采纳,获得50
7秒前
在水一方的应助被可靠半雪采纳,获得30
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187076
求助须知:如何正确求助?哪些是违规求助? 9575330
关于积分的说明 21840572
捐赠科研通 7784821
什么是DOI,文献DOI怎么找? 3434919
关于科研通互助平台的介绍 2559308
邀请新用户注册赠送积分活动 2481777